Takeda Pharmaceutical Co Ltd ADR (TAK)vsUnited Therapeutics Corporation (UTHR)
TAK
Takeda Pharmaceutical Co Ltd ADR
$17.82
-1.60%
HEALTHCARE · Cap: $57.56B
UTHR
United Therapeutics Corporation
$524.28
-0.52%
HEALTHCARE · Cap: $23.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 140176% more annual revenue ($4.46T vs $3.18B). UTHR leads profitability with a 41.9% profit margin vs 2.5%. TAK appears more attractively valued with a PEG of 0.40. UTHR earns a higher WallStSmart Score of 67/100 (B-).
TAK
Buy60
out of 100
Grade: C
UTHR
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$17.82
$7.52 premium
Margin of Safety
+63.2%
Fair Value
$1294.44
Current Price
$524.28
$770.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Every $100 of equity generates 150 in profit
Earnings expanding 330.2% YoY
Generating 317.5B in free cash flow
Large-cap with strong market position
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 45.0%
Safe zone — low bankruptcy risk
Earnings expanding 24.5% YoY
Areas to Watch
4.2% revenue growth
2.5% margin — thin
Premium valuation, high expectations priced in
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Return on Equity. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.9% and operating margin at 45.0%.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Profit Margin, P/E Ratio. A P/E of 82.8x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio.
Key Dynamics to Monitor
TAK profiles as a value stock while UTHR is a mature play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.86 — expect wider price swings.
UTHR is growing revenue faster at 7.4% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (67/100 vs 60/100), backed by strong 41.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?